Philadelphia Pharmaceuticals Co. (PHIL) Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: Philadelphia Pharmaceuticals Co. has changed its score on 25 Nov 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Jun 25

DEBTORS TURNOVER RATIO(HY) Lowest at 1.26%

With ROE of 7.02%, it has a attractive valuation with a 0.00 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JOD Million (Small Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.03

Return on Equity

6.93%

Price to Book

0.00

Revenue and Profits:

Net Sales:

2 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

4.73%

6 Months

6.16%

1 Year

3.33%

2 Years

8.39%

3 Years

21.09%

4 Years

13.14%

5 Years

12.32%

Philadelphia Pharmaceuticals Co. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Philadelphia Pharmaceuticals Co. Upgraded to 'Hold' Amid Mixed Technical Indicators

Philadelphia Pharmaceuticals Co. has transitioned from a 'Not Rated' status to a 'Hold' designation by MarketsMOJO, reflecting a revised evaluation of its valuation and technical metrics. The company maintains a fair valuation and has shown stable financial performance, despite underperforming the broader market over the past year.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.97%

EBIT Growth (5y)

4.45%

EBIT to Interest (avg)

1.03

Debt to EBITDA (avg)

0.32

Net Debt to Equity (avg)

0.05

Sales to Capital Employed (avg)

0.58

Tax Ratio

21.07%

Dividend Payout Ratio

63.93%

Pledged Shares

Institutional Holding

ROCE (avg)

7.95%

ROE (avg)

4.90%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

0.63

EV to EBITDA

0.50

EV to Capital Employed

0.07

EV to Sales

0.10

PEG Ratio

Dividend Yield

ROCE (Latest)

10.62%

ROE (Latest)

7.02%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 14.29% vs 0.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 50.00% vs 0.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.40",
          "val2": "2.10",
          "chgp": "14.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.60",
          "val2": "0.40",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.30",
          "val2": "0.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "173.10%",
          "val2": "177.10%",
          "chgp": "-0.40%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 4.76% vs 0.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 14.29% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.80",
          "val2": "8.40",
          "chgp": "4.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.70",
          "val2": "1.90",
          "chgp": "-10.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.30",
          "chgp": "33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.80",
          "val2": "0.80",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "159.40%",
          "val2": "161.20%",
          "chgp": "-0.18%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

2.40

2.10

14.29%

Operating Profit (PBDIT) excl Other Income

0.60

0.40

50.00%

Interest

0.10

Exceptional Items

0.00

Consolidate Net Profit

0.30

0.20

50.00%

Operating Profit Margin (Excl OI)

173.10%

177.10%

-0.40%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 14.29% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 50.00% vs 0.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

8.80

8.40

4.76%

Operating Profit (PBDIT) excl Other Income

1.70

1.90

-10.53%

Interest

0.40

0.30

33.33%

Exceptional Items

0.00

Consolidate Net Profit

0.80

Operating Profit Margin (Excl OI)

159.40%

161.20%

-0.18%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 4.76% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 0.00% vs 14.29% in Dec 2023

All Annual Results

Company CV

About Philadelphia Pharmaceuticals Co.

Philadelphia Pharmaceuticals Co.

Pharmaceuticals & Biotechnology

Philadelphia Pharmaceuticals Industry Company PSC is a Jordan-based company that is engaged in the development, manufacture and marketing of human pharmaceutical products of different therapeutic categories. The Company, through its production facilities and laboratories located in Amman Industrial state, develops and produces a number of products that includes: Semisolid Dosage Forms, such as creams, ointments, lotions, gels and suppositories, as well as Liquid Dosage Forms, which include syrups, suspensions, solutions, nasal, drops, mouth washes and vaginal douches. Furthermore, the Company undertakes the distribution and marketing of a range of healthcare systems, miscellaneous and pharmaceuticals of different international brand names, including alimentary, gastrointestinal systems and respiratory systems. The Company markets its products to the local markets and exports to more than 10 countries in the Middle East and North Africa region.

Company Coordinates

Company Details

Str 10,Shb Kng Abdlh Ibn Al Hn 2 Ind Cty, Street 10, King Abdullah 2 Indstl City, P.O.Box 276, AMMAN None : 11512

Tel: 962 6 4029181

http://www.philapharma.com/

Registrar Details

Philadelphia Pharmaceuticals Co.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Flat results in Jun 25

With ROE of 7.02%, it has a attractive valuation with a 0.00 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Philadelphia Pharmaceuticals Co. Upgraded to 'Hold' Amid Mixed Technical Indicators

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Philadelphia Pharmaceuticals Co.

Company Coordinates